Table 2 Outcomes in newly diagnosed and relapsed/refractory patients with IDH2 mutant acute myeloid leukemia.
Response | Newly diagnosed n = 7 | Relapsed/refractory n = 19 |
|---|---|---|
CRc | 7 (100) | 11 (58) |
CR | 5 (72) | 5 (26) |
CRi | 2 (28) | 6 (32) |
MRD negativity by FCM | 7/7 (100) | 2/9 (22) |
Not evaluable | 0 | 1 (5) |
No response | 0 | 7 (37) |
Median number of cycles given (range) | 3 (1–8) | 4 (1–17) |
Median time to best response, months (range) | 1.6 (1.0–4.2) | 1.8 (0.8–5.4) |
